Psoriasis vulgaris is the most common form of psoriasis. It causes patches of scaly, inflamed skin and can occur across the body. Vulgaris is Latin for ‘common’, so it means a common form of psoriasis ...

Please provide your email address to receive an email when new articles are posted on . Water-free, lipid-based spray formulations of calcipotriol were efficacious and safe in psoriasis vulgaris ...

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis (Psoriasis Vulgaris) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This ...

Psoriasis and psoriatic arthritis show genetic predispositions, but genetic influences on clinical characteristics are poorly understood. In a study conducted in Japan, patients with psoriasis and a ...

A Mendelian randomization study found that there appears to be a causal relationship between inflammatory bowel disease (IBD) and psoriasis. A study published in Frontiers in Immunology found that ...

MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved ...

Ten-year mean costs associated with psoriasis-related health care visits were 10 times higher for patients with generalized pustular psoriasis (GPP). Patients with generalized pustular psoriasis (GPP) ...

—In Israel, researchers recently examined which of several common comorbidities were more likely to occur in patients with palmoplantar plaque psoriasis. One in particular was unexpected. Plaque ...

Purpose To investigate the validity of direct and indirect health state utility (HSU) and subjective well-being measures in psoriasis vulgaris patients. Methods A convenience sampling framework was ...

Knight obtained the Canadian rights to WYNZORA ® through its June 2025 acquisition of the assets of Paladin Pharma Inc. (“Paladin”). In November 2024, Paladin had entered into a license agreement with ...